These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25637517)

  • 1. Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation.
    Todesco E; Mercier-Darty M; Jung M; Bottero J; Boyd A; Marcelin AG; Calvez V; Morand-Joubert L
    J Antimicrob Chemother; 2015; 70(6):1919-20. PubMed ID: 25637517
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure.
    Mohamed S; Penaranda G; Gonzalez D; Camus C; Khiri H; Boulmé R; Sayada C; Philibert P; Olive D; Halfon P
    AIDS; 2014 Jun; 28(9):1315-24. PubMed ID: 24698843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
    Todesco E; Rodriguez C; Morand-Joubert L; Mercier-Darty M; Desire N; Wirden M; Girard PM; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2015 May; 70(5):1503-6. PubMed ID: 25614045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
    Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
    J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of human immunodeficiency virus resistance tests in clinical practice.
    Ceccherini-Silberstein F; Cento V; Calvez V; Perno CF
    Clin Microbiol Infect; 2010 Oct; 16(10):1511-7. PubMed ID: 20731678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.
    Raymond S; Nicot F; Carcenac R; Lefebvre C; Jeanne N; Saune K; Delobel P; Izopet J
    J Antimicrob Chemother; 2018 May; 73(5):1152-1157. PubMed ID: 29444253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and significance of minority quasispecies of drug-resistant HIV-1.
    Metzner KJ
    J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210
    [No Abstract]   [Full Text] [Related]  

  • 8. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Description of two commercially available assays for genotyping of HIV-1.
    Stürmer M; Reinheimer C
    Intervirology; 2012; 55(2):134-7. PubMed ID: 22286883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation.
    Jaffré J; Armenia D; Bellocchi MC; Wirden M; Carioti L; Lambert S; Valantin MA; Nguyen T; Simon A; Katlama C; Andreoni M; Perno CF; Calvez V; Ceccherini-Silberstein F; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2017 May; 72(5):1537-1539. PubMed ID: 28088769
    [No Abstract]   [Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
    Stelzl E; Pröll J; Bizon B; Niklas N; Danzer M; Hackl C; Stabentheiner S; Gabriel C; Kessler HH
    J Virol Methods; 2011 Dec; 178(1-2):94-7. PubMed ID: 21907239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania.
    Fall-Malick FZ; Tchiakpé E; Ould Soufiane S; Diop-Ndiaye H; Mouhamedoune Baye A; Ould Horma Babana A; Touré Kane C; Lo B; Mboup S
    J Med Virol; 2014 Mar; 86(3):404-10. PubMed ID: 24318486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Roche prototype 454 HIV-1 ultradeep sequencing drug resistance assay in a routine diagnostic laboratory.
    Garcia-Diaz A; Guerrero-Ramos A; McCormick AL; Macartney M; Conibear T; Johnson MA; Haque T; Webster DP
    J Clin Virol; 2013 Oct; 58(2):468-73. PubMed ID: 23954217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dried blood spots for HIV-1 drug resistance genotyping in decentralized settings in Senegal.
    Diouara AA; Diop-Ndiaye H; Kebe-Fall K; Tchiakpè E; Ndiaye O; Ayouba A; Peeters M; Mboup S; Kane CT
    J Med Virol; 2014 Jan; 86(1):45-51. PubMed ID: 24122937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
    Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay.
    Péré H; Roques P; Talla F; Meillo H; Charpentier C; Bélec L
    AIDS; 2015 Jun; 29(10):1267-9. PubMed ID: 26035326
    [No Abstract]   [Full Text] [Related]  

  • 18. When do minority drug-resistant HIV-1 variants have a major clinical impact?
    Heneine W
    J Infect Dis; 2010 Mar; 201(5):647-9. PubMed ID: 20102273
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of a cost-effective assay for genotyping of HIV-1 non-B subtype for drug resistance.
    Ammaranond P; Sanguansittianant S; Raju PA; Cunningham P; Horthongkham N
    J Virol Methods; 2014 Apr; 199():102-7. PubMed ID: 24462843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen.
    Todesco E; Surgers L; Marcelin AG; Calvez V; Meynard JL; Morand-Joubert L
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):e43-5. PubMed ID: 26818741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.